We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have lost about 30.3% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Sarepta Therapeutics (SRPT) stock is reeling this week following the death of a 16-year-old patient treated with its flagship gene therapy, Elevidys. As the news broke on Tuesday, SRPT investors ...

Cantor Fitzgerald reiterated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a ...

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price lowered by Scotiabank from $105.00 to $80.00 in a ...

In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) stands against other Wednesday’s top performers. The stock market regained momentum on Wednesday ...

Sarepta Therapeutics said a patient taking its treatment for Duchenne muscular dystrophy has died from acute liver failure.

In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) stands against other firms heavily hit by market pessimism. Wall Street finished in the red territory ...

We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options ...

The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.